Export 136 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U [V] W X Y Z   [Show ALL]
Vogl, T. J., A. Zinn, E. Elhawash, L. S. Alizadeh, N. - E. A. Nour-Eldin, and N. N. N. Naguib, "MR angiography-planned prostatic artery embolization for benign prostatic hyperplasia: single-center retrospective study in 56 patients.", Diagnostic and interventional radiology (Ankara, Turkey), vol. 27, issue 6, pp. 725-731, 2021. Abstractdir-27-6-725_1.pdf

PURPOSE: We aimed to evaluate the advantages of magnetic resonance angiography (MRA)-planned prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH).

METHODS: In this retrospective study, MRAs of 56 patients (mean age, 67.23±7.73 years; age range, 47-82 years) who underwent PAE between 2017 and 2018 were evaluated. For inclusion, full information about procedure time and radiation values must have been available. To identify prostatic artery (PA) origin, three-dimensional MRA reconstruction with maximum intensity projection was conducted in every patient. In total, 33 patients completed clinical and imaging follow-up and were included in clinical evaluation.

RESULTS: There were 131 PAs with a second PA in 19 pelvic sides. PA origin was correctly identified via MRA in 108 of 131 PAs (82.44%). In patients in which MRA allowed a PA analysis, a significant reduction of the fluoroscopy time (-27.0%, p = 0.028) and of the dose area product (-38.0%, p = 0.003) was detected versus those with no PA analysis prior to PAE. Intervention time was reduced by 13.2%, (p = 0.25). Mean fluoroscopy time was 30.1 min, mean dose area product 27,749 µGy•m2, and mean entrance dose 1553 mGy. Technical success was achieved in all 56 patients (100.0%); all patients were embolized on both pelvic sides. The evaluated data documented a significant reduction in IPSS (p < 0.001; mean 9.67 points).

CONCLUSION: MRA prior to PAE allowed the identification of PA in 82.44% of the cases. MRA-planned PAE is an effective treatment for patients with BPH.

Vogl, T. J., N. - E. A. Nour-Eldin, R. M. Hammerstingl, B. Panahi, and N. N. N. Naguib, "Microwave Ablation (MWA): Basics, Technique and Results in Primary and Metastatic Liver Neoplasms - Review Article.", RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, vol. 189, issue 11, pp. 1055-1066, 2017 Nov. Abstract

 The locoregional interventional oncological treatment approach is an accepted modality for liver neoplasms, especially for hepatocellular carcinoma (HCC) and oligonodular liver metastases.  The main aim of ablation therapies like microwave ablation (MWA) is to eradicate all malignant cells in a minimally invasive technique under imaging guidance while preserving the healthy tissue with a sufficient safety margin (at least 5 mm) surrounding the ablated lesion.  Ablation therapy can be performed via a percutaneous, laparoscopic or intraoperative approach under ultrasound, MRI or CT guidance for adequate localization and monitoring of the ablation process.  Ablation is the method of choice for oligonodular HCCs ≤ 3 cm. The technical success rate varies from 88 % to 98 % and progression-free survival (PFS) at 3 years from 27 % to 91.7 %. The same criteria apply to the therapy of liver metastases.   · Careful selection of patients proves to be essential for optimum results of MWA. · Interventionists should be familiar with all aspects of complication and rapid assessment of imaging methods in order to evaluate induced damage by thermal ablation. · MWA seems to have some advantages over radiofrequency ablation, like shorter ablation time, less pain, less heat sink effect; however, scientific proof is needed. · Vogl TJ, Nour-Eldin A, Hammerstingl RM et al. Microwave Ablation (MWA): Basics, Technique and Results in Primary and Metastatic Liver Neoplasms - Review Article. Fortschr Röntgenstr 2017; 189: 1055 - 1066.

Vogl, T. J., N. - E. Nour-Eldin, S. Emad-Eldin, N. N. N. Naguib, J. Trojan, H. Ackermann, and O. Abdelaziz, "Portal Vein Thrombosis and Arterioportal Shunts: Effects on Tumor Response After Chemoembolization of Hepatocellular Carcinoma", World J. gastroenterol, vol. 17, issue 10, pp. 1267–1275, 2011. AbstractCU-PDF.pdf

IF: 2.240

Voils, S. A., E. J. Martin, B. M. Mohammed, A. Bayrlee, and D. F. Brophy, "Laboratory assessment of warfarin reversal with global coagulation tests versus international normalized ratio in patients with intracranial bleeding", Blood Coagulation & Fibrinolysis, vol. 26, issue 4: LWW, pp. 443-447, 2015. Abstract
Voils, S. A., E. J. Martin, B. M. Mohammed, A. Bayrlee, and D. F. Brophy, Laboratory assessment of warfarin reversal with global coagulation tests versus international normalized ratio in patients with intracranial bleeding, , vol. 26, issue 4: LWW, pp. 443 - 447, 2015. Abstract
Vongchan, P., M. Warda, H. Toyoda, T. Toida, R. M. Marks, and R. J. Linhardt, "Structural characterization of human liver heparan sulfate.", Biochimica et biophysica acta, vol. 1721, issue 1-3, pp. 1-8, 2005 Jan 18. Abstract

The isolation, purification and structural characterization of human liver heparan sulfate are described. 1H-NMR spectroscopy demonstrates the purity of this glycosaminoglycan (GAG) and two-dimensional 1H-NMR confirmed that it was heparan sulfate. Enzymatic depolymerization of the isolated heparan sulfate, followed by gradient polyacrylamide gel, confirmed its heparin lyase sensitivity. The concentration of resulting unsaturated disaccharides was determined using reverse phase ion-pairing (RPIP) HPLC with post column derivatization and fluorescence detection. The results of this analysis clearly demonstrate that the isolated GAG was heparan sulfate, not heparin. Human liver heparan sulfate was similar to heparin in that it has a reduced content of unsulfated disaccharide and an elevated average sulfation level. The antithrombin-mediated anti-factor Xa activity of human liver heparan sulfate, however, was much lower than porcine intestinal (pharmaceutical) heparin but was comparable to standard porcine intestinal heparan sulfate. Moreover, human liver heparan sulfate shows higher degree of sulfation than heparan sulfate isolated from porcine liver or from the human hepatoma Hep 2G cell line.

Vosoughi, A., T. Zhang, K. S. Shohdy, P. J. Vlachostergios, D. C. Wilkes, B. Bhinder, S. T. Tagawa, D. M. Nanus, A. M. Molina, H. Beltran, et al., "Common germline-somatic variant interactions in advanced urothelial cancer", Nature Communications, vol. 11, issue 1, pp. 6195 - 6195, 2020/12//. Abstract

The prevalence and biological consequences of deleterious germline variants in urothelial cancer (UC) are not fully characterized. We performed whole-exome sequencing (WES) of germline DNA and 157 primary and metastatic tumors from 80 UC patients. We developed a computational framework for identifying putative deleterious germline variants (pDGVs) from WES data. Here, we show that UC patients harbor a high prevalence of pDGVs that truncate tumor suppressor proteins. Deepening somatic loss of heterozygosity in serial tumor samples is observed, suggesting a critical role for these pDGVs in tumor progression. Significant intra-patient heterogeneity in germline-somatic variant interactions results in divergent biological pathway alterations between primary and metastatic tumors. Our results characterize the spectrum of germline variants in UC and highlight their roles in shaping the natural history of the disease. These findings could have broad clinical implications for cancer patients.

de Vries, N. L., V. van Unen, M. E. Ijsselsteijn, T. Abdelaal, R. van der Breggen, A. Farina Sarasqueta, A. Mahfouz, K. C. M. J. Peeters, T. Höllt, B. P. F. Lelieveldt, et al., "High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity.", Gut, 2019. Abstract

OBJECTIVE: A comprehensive understanding of anticancer immune responses is paramount for the optimal application and development of cancer immunotherapies. We unravelled local and systemic immune profiles in patients with colorectal cancer (CRC) by high-dimensional analysis to provide an unbiased characterisation of the immune contexture of CRC.

DESIGN: Thirty-six immune cell markers were simultaneously assessed at the single-cell level by mass cytometry in 35 CRC tissues, 26 tumour-associated lymph nodes, 17 colorectal healthy mucosa and 19 peripheral blood samples from 31 patients with CRC. Additionally, functional, transcriptional and spatial analyses of tumour-infiltrating lymphocytes were performed by flow cytometry, single-cell RNA-sequencing and multispectral immunofluorescence.

RESULTS: We discovered that a previously unappreciated innate lymphocyte population (LinCD7CD127CD56CD45RO) was enriched in CRC tissues and displayed cytotoxic activity. This subset demonstrated a tissue-resident (CD103CD69) phenotype and was most abundant in immunogenic mismatch repair (MMR)-deficient CRCs. Their presence in tumours was correlated with the infiltration of tumour-resident cytotoxic, helper and γδ T cells with highly similar activated (HLA-DRCD38PD-1) phenotypes. Remarkably, activated γδ T cells were almost exclusively found in MMR-deficient cancers. Non-activated counterparts of tumour-resident cytotoxic and γδ T cells were present in CRC and healthy mucosa tissues, but not in lymph nodes, with the exception of tumour-positive lymph nodes.

CONCLUSION: This work provides a blueprint for the understanding of the heterogeneous and intricate immune landscape of CRC, including the identification of previously unappreciated immune cell subsets. The concomitant presence of tumour-resident innate and adaptive immune cell populations suggests a multitargeted exploitation of their antitumour properties in a therapeutic setting.

Vural, A., H. Negm, and C. Vicini, "Rebotic Surgery of Skull Base", All Around the Nose: Springer, 2020.
Vwioko, E. D., M. A. El-Esawi, M. E. Imoni, A. A. Al-Ghamdi, H. M. Ali, M. M. El-Sheekh, E. A. Abdeldaym, and M. A. Al-Dosary, "Sodium Azide Priming Enhances Waterlogging Stress Tolerance in Okra (Abelmoschus esculentus L.)", Agronomy, vol. 9, no. 11: Multidisciplinary Digital Publishing Institute, pp. 679, 2019. Abstract